Kazia Therapeutics Limited (Nasdaq: KZIA), a clinical-stage oncology company advancing therapies to reprogram cancer biology and overcome treatment resistance, announces the in-licensing of a first-in ...

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical company, today announced positive data from its HT-VA study, conducted under its Cooperative Research and Development ...

Yuancheng Ryan Lu could barely breathe while he waited for his labmate to adjust the microscope focus. On the slide in front ...

Researchers at Oregon Health & Science University have uncovered a key reason why immunotherapy has largely failed in ...

St. Jude Children's Research Hospital scientists have discovered how tumors disable immune "gatekeeper" cells that alert the ...

Scientists at Life Biosciences are preparing to begin testing partial reprogramming in people. It will mark the first time ...

Lockheed Martin Corp. (NYSE:LMT) has secured two contract modifications from the U.S. Department of War totaling $91,867,982.

From billionaire-backed biotech to promising animal studies, this early trial will test whether partial reprogramming can ...

Board of Alders New Haven Notice] The Joint Community Development/Health & Human Services Committee will meet in person on Wednesday, April 15, 2026, at 6:00 P.M, in the Board of Alders Chamber, 165 ...

India, April 13 -- Life Biosciences, a clinical-stage biotechnology company focused on reversing diseases of aging, has received clearance from the U.S. Food and Drug Administration (FDA)-the ...

Advances in iPSC technology and in vivo reprogramming are expanding the possibilities for cell therapy. Explore the science ...